Recurrent Endometrial Carcinoma Clinical Trials

44 clinical trials for Recurrent Endometrial Carcinoma across international registries, including 11 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma — RECRUITING · PHASE2
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial — RECRUITING · PHASE2
• Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer — RECRUITING · PHASE3
• Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma — RECRUITING · PHASE1
• Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer — RECRUITING · PHASE2
• Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer — RECRUITING · PHASE1
• Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform — RECRUITING
• Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers — RECRUITING · PHASE1
• Avelumab and M1774 in ARID1A-mutated Endometrial Cancer — RECRUITING · PHASE2
• Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer — RECRUITING · PHASE2
• First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer — RECRUITING · PHASE2
• Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer — COMPLETED · PHASE1
• VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer — NOT_YET_RECRUITING · PHASE2
• Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation — TERMINATED · PHASE2
• Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers — ACTIVE_NOT_RECRUITING · PHASE1
• Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis — COMPLETED · PHASE1
• Endometrial Cancer Recurrence in Patients Taking Metformin — WITHDRAWN
• Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer — TERMINATED · PHASE1
• Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma — COMPLETED · PHASE2
• Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers — TERMINATED · PHASE1
• Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290 — COMPLETED
• Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer — COMPLETED · PHASE2
• Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer — COMPLETED · PHASE2
• Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer — COMPLETED · PHASE2
• Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer — COMPLETED · PHASE2
• VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer — COMPLETED · PHASE2
• Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors — COMPLETED · PHASE1
• Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer — COMPLETED · NA
• Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer — COMPLETED · PHASE1
• Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer — COMPLETED · PHASE2
• Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer — WITHDRAWN · PHASE2
• Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors — COMPLETED · PHASE1
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors — COMPLETED · PHASE1
• Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies — COMPLETED · PHASE2
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) — COMPLETED · PHASE1
• Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors — COMPLETED · PHASE1
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu — COMPLETED · PHASE1
• Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer — COMPLETED · PHASE2

Refine this search